Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON30316
NL-OMON30316
Not yet recruiting
Not Applicable

Biomarker detection for benign breast diseases and primary breast cancer by serum and tissue protein profiling. - Breast Cancer Proteomics study (BCP study)

Slotervaartziekenhuis0 sites380 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsbenign breast diseasesbreast cancer10006291

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
benign breast diseases
Sponsor
Slotervaartziekenhuis
Enrollment
380
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Sponsor
Slotervaartziekenhuis

Eligibility Criteria

Inclusion Criteria

  • •1\. Female patients diagnosed with benign breast disease or primary breast cancer (that will be treated surgically) by breast biopsy at the Department of Surgery of the Slotervaart Hospital in Amsterdam.
  • •2\. Female patients diagnosed with benign breast disease and treated surgically the Department of Surgery of the Slotervaart Hospital in Amsterdam.
  • •3\. Female patients undergoing breast reduction surgery at the Department of Plastic Surgery of the Slotervaart Hospital in Amsterdam.
  • •4\. Age \> 18yrs.
  • •5\. Able and willing to undergo blood and tissue sampling for protein analysis.

Exclusion Criteria

  • •1\. Known history of (treated) malignancies.
  • •2\. Incapacity of participant to give written informed consent.
  • •3\. Patients not able to undergo blood and tissue sampling for protein analysis.
  • •4\. Any psychological, familial, sociological or geographical condition that may potentially interfere with compliance to the study protocol.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Detection of early premalignant breast lesions by autofluorescence ductoscopy
NL-OMON40131niversitair Medisch Centrum Utrecht30
Completed
Not Applicable
Improved diagnosis of clinically occult breast lesionsbreast neoplasmsbreast cancer10006291
NL-OMON38092niversitair Medisch Centrum Utrecht128
Active, not recruiting
Phase 1
Multihance versus Dotarem at 3 Teslathe aim of this study is to intraindividually compare the use of equivalent doses of gadobenate dimeglumine (MultiHance, Bracco Imaging, Milan, Italy) and gadoterate meglumine (DOTAREM, Guerbet, France) for breast MR imaging by using a prospective study design, evaluated independently by blinded readers.Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2011-005498-21-ATMed. Univ. Wien, Univ. Klinik für Radiodiagnostik130
Completed
Not Applicable
Detectability of breast lesions of dense breast using low-dose computed tomographyBreast lesions
JPRN-UMIN000029145Hokkaido University80
Active, not recruiting
Not Applicable
Breast cancer biomarkers and treatment targetsBreast cancerCancerMalignant neoplasm of breast
ISRCTN40576403niversity Hospital Southampton (UK)500